BEAM
$25.83
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogen...
Recent News
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.
RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here’s Why
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, RBC Capital adjusted the price target on Beam Therapeutics Inc. (NASDAQ:BEAM) to $26 from $22 and maintained a Sector Perform rating on the shares. The rating update came after the company reported its fiscal Q4 […]
Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing
Beam Therapeutics (NasdaqGS:BEAM) launched BEAM-304, a new base-editing genetic medicine program for phenylketonuria, expanding its liver-targeted portfolio. The company entered a $500 million non-dilutive credit facility with Sixth Street to support the anticipated launch of its sickle cell therapy candidate, risto-cel. Beam reported continued progress across its clinical pipeline alongside these updates. Beam Therapeutics is drawing fresh attention as it adds a new program for...
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
Beam Therapeutics Inc. Q4 2025 Earnings Call Summary
Moby summary of Beam Therapeutics Inc.'s Q4 2025 earnings call